Ravinay Bhindi

Ravinay Bhindi

Auto-generated profile, based on publicly available information

Ravinay Bhindi

Department of Cardiology, Royal North Shore Hospital, Sydney, Australia; University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MBMuntasir Billah
Muntasir Billah
ARAnisyah Ridiandries
Anisyah Ridiandries
UAUsaid K Allahwala
Usaid K Allahwala
HMHarshini Mudaliar
Harshini Mudaliar
ADAnthony Dona
Anthony Dona
RBRavinay Bhindi
Ravinay Bhindi
Autophagy is a cellular process by which mammalian cells degrade and assist in recycling damaged organelles and proteins. This study aimed to ascertain the role of autophagy in remote ischemic preconditioning (RIPC)-induced cardioprotection. Sprague Dawley rats were subjected to RIPC at the hindlimb followed by a 30-min transient blockade of the left coronary artery to simulate ischemia reperfusion (I/R) injury. Hindlimb muscle and the heart were excised 24 h post reperfusion. RIPC prior to I/R upregulated autophagy in the rat heart at 24 h post reperfusion. In vitro, autophagy inhibition or stimulation prior to RIPC, respectively, either ameliorated or stimulated the cardioprotective effect, measured as improved cell viability to mimic the preconditioning effect. Recombinant interleukin-6 (IL-6) treatment prior to I/R increased in vitro autophagy in a dose-dependent manner, activating the Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway without affecting the other kinase pathways, such as p38 mitogen-activated protein kinases (MAPK), and glycogen synthase kinase 3 Beta (GSK-3β) pathways. Prior to I/R, in vitro inhibition of the JAK-STAT pathway reduced autophagy upregulation despite recombinant IL-6 pre-treatment. Autophagy is an essential component of RIPC-induced cardioprotection that may upregulate autophagy through an IL-6/JAK-STAT-dependent mechanism, thus identifying a potentially new therapeutic option for the treatment of ischemic heart disease.

22 August 2013 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
BRBenjamin S. Rayner
Benjamin S. Rayner
GFGemma A. Figtree
Gemma A. Figtree
TSTharani Sabaretnam
Tharani Sabaretnam
PSPing Shang
Ping Shang
JMJawad Mazhar
Jawad Mazhar
RBRavinay Bhindi
Ravinay Bhindi
Background: Egr‐1 is implicated in the pathogenesis of myocardial ischemia–reperfusion injury. The aim of this study was to ascertain the effectiveness of intracoronary delivery of DNA zyme targeting the transcription factor Egr‐1 at reperfusion following experimental myocardial ischemia. Methods and Results: Functional DNA zyme targeting Egr‐1 or a size‐matched scrambled control were delivered via the intracoronary route immediately on reperfusion after 60 minutes' balloon occlusion of the left anterior descending coronary artery in a pig model of myocardial I/R injury (n=7 per treatment group). Heart function and extent of myocardial infarction were determined following intervention by echocardiography and cardiac magnetic resonance imaging, respectively. Hearts were removed and examined for molecular and histological markers of inflammation and apoptosis. Administration of functional DNA zyme led to an overall decrease in the expression of inflammatory markers including intracellular adhesion molecule‐1, tissue factor, and complement 3, with associated decreases in the extent of neutrophil infiltration, oxidative damage, and subsequent apoptosis within the infarct border zone. Functional significance was indicated by an increase in salvaged left ventricular myocardium ( P =0.012), ejection fraction ( P =0.002), and fractional area change ( P =0.039) in the functional DNA zyme–treated group compared with the control. Conclusions: Egr‐1 silencing through intracoronary delivery of a targeting DNA zyme at the time of reperfusion following acute myocardial ischemia decreases myocardial inflammation and apoptosis leading to improved cardiac function.

31 August 2011 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
RBRavinay Bhindi
Ravinay Bhindi
RFRoger G Fahmy
Roger G Fahmy
AMAisling C McMahon
Aisling C McMahon
Levon Michael KhachigianLevon Michael Khachigian
Levon Michael Khachigian
HLHarry C Lowe
Harry C Lowe

5 July 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
HSHari P. Sritharan
Hari P. Sritharan
KBKunwardeep S. Bhatia
Kunwardeep S. Bhatia
WGWilliam van Gaal
William van Gaal
LKLeonard Kritharides
Leonard Kritharides
CCClara K. Chow
Clara K. Chow
RBRavinay Bhindi
Ravinay Bhindi
Background: Pre-existing cardiovascular disease and cardiovascular risk factors are common in patients with COVID-19 and there remain concerns for poorer in-hospital outcomes in this cohort. We aimed to analyse the relationship between pre-existing cardiovascular disease, mortality and cardiovascular outcomes in patients hospitalised with COVID-19 in a prospective, multicentre observational study.Method: This prospective, multicentre observational study included consecutive patients of age ≥18 in their index hospitalisation with laboratory-proven COVID-19 in Australia. Patients with suspected but not laboratory-proven COVID-19 and patients with no available past medical history were excluded. The primary exposure was pre-existing cardiovascular disease, defined as a composite of coronary artery disease, heart failure or cardiomyopathy, atrial fibrillation or flutter, severe valvular disease, peripheral arterial disease and stroke or transient ischaemic attack. The primary outcome was in-hospital mortality. Secondary outcomes were clinical cardiovascular complications (new onset atrial fibrillation or flutter, high-grade atrioventricular block, sustained ventricular tachycardia, new heart failure or cardiomyopathy, pericarditis, myocarditis or myopericarditis, pulmonary embolism and cardiac arrest) and myocardial injury.Results: 1,567 patients (mean age 60.7 (±20.5) years and 837 (53.4%) male) were included. Overall, 398 (25.4%) patients had pre-existing cardiovascular disease, 176 patients (11.2%) died, 75 (5.7%) had clinical cardiovascular complications and 345 (37.8%) had myocardial injury. Patients with pre-existing cardiovascular disease had significantly increased in-hospital mortality (aOR: 1.76 95% CI: 1.21–2.55, p = 0.003) and myocardial injury (aOR: 3.27, 95% CI: 2.23–4.79, p < 0.001). There was no significant association between pre-existing cardiovascular disease and in-hospital clinical cardiovascular complications (aOR: 1.10, 95% CI: 0.58–2.09, p = 0.766). On mediation analysis, the indirect effect and Sobel test were significant (p < 0.001), indicating that the relationship between pre-existing cardiovascular disease and in-hospital mortality was partially mediated by myocardial injury. Apart from age, other cardiovascular risk factors such as diabetes, hypercholesterolemia and hypertension had no significant impact on mortality, clinical cardiovascular complications or myocardial injury.Conclusions: Pre-existing cardiovascular disease is associated with significantly higher mortality in patients hospitalised with COVID-19. This relationship may be partly explained by increased risk of myocardial injury among patients with pre-existing cardiovascular disease which in turn is a marker associated with higher mortality.

2 September 2021 in Heart, Lung and Circulation
Verified
Journal Article
Open access
KBKunwardeep S. Bhatia
Kunwardeep S. Bhatia
HSHari P. Sritharan
Hari P. Sritharan
JCJustin Chia
Justin Chia
JCJonathan Ciofani
Jonathan Ciofani
DNDaniel Nour
Daniel Nour
RBRavinay Bhindi
Ravinay Bhindi
Describe the incidence of cardiac complications in patients admitted to hospital with COVID-19 in Australia. Observational cohort study. Twenty-one (21) Australian hospitals. Consecutive patients aged ≥18 years admitted to hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Incidence of cardiac complications. Six-hundred-and-forty-four (644) hospitalised patients (62.5±20.1 yo, 51.1% male) with COVID-19 were enrolled in the study. Overall in-hospital mortality was 14.3%. Twenty (20) (3.6%) patients developed new atrial fibrillation or flutter during admission and 9 (1.6%) patients were diagnosed with new heart failure or cardiomyopathy. Three (3) (0.5%) patients developed high grade atrioventricular (AV) block. Two (2) (0.3%) patients were clinically diagnosed with pericarditis or myopericarditis. Among the 295 (45.8%) patients with at least one troponin measurement, 99 (33.6%) had a peak troponin above the upper limit of normal (ULN). In-hospital mortality was higher in patients with raised troponin (32.3% vs 6.1%, p<0.001). New onset atrial fibrillation or flutter (6.4% vs 1.0%, p=0.001) and troponin elevation above the ULN (50.3% vs 16.4%, p<0.001) were more common in patients 65 years and older. There was no significant difference in the rate of cardiac complications between males and females. Among patients with COVID-19 requiring hospitalisation in Australia, troponin elevation was common but clinical cardiac sequelae were uncommon. The incidence of atrial arrhythmias and troponin elevation was greatest in patients 65 years and older.

1 April 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
ESElizabeth Shaw
Elizabeth Shaw
UAUsaid K. Allahwala
Usaid K. Allahwala
JCJames A. Cockburn
James A. Cockburn
THThomas C.E. Hansen
Thomas C.E. Hansen
JMJawad Mazhar
Jawad Mazhar
RBRavinay Bhindi
Ravinay Bhindi